Print: established name once per page or spread when running text spans multiple pages

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

Where the proprietary name is not featured but appears only in running text, and that running text spans more than one page or spread, FDA recommends that the established name accompany the proprietary name at least once per page or spread.

Check

For multi-page or multi-spread running text in which the proprietary name is not featured, confirm the established name appears at least once per page or spread.

Escalate when

Reviewer is unsure whether the material constitutes a single spread or multiple separate pages/spreads.

Where this comes from

Section II.D.1 · page 8. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… name in a headline, FDA does not intend to object if the established name does not also follow the proprietary name in sub-headlines, appear in the running text on the same page or spread, or appear in columns on the same page or spread. If the proprietary name is not featured but is only part of the running text, the established name is required to accompany the proprietary name at least once in the running text. If the running text spans more than one page or spread, FDA recommends that the established name accompany the proprietary name at least once per page or spread. The regulations in 21 CFR 201.10(g)(1) and 202.1(b)(1) include information regarding the frequency of the proprietary and established names if columns are used in a promotional labeling piece or advertisement (e.g., a newspaper advertisement). FDA interprets a column to mean one of two or more vertical sections of a printed page, separated by a rule or blank space. If the proprietary name appears in more than one…

Open the original at page 8 on fda.gov ↗Read our full copy →

Document: FDA guidance: Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: f6f78606542ef91596ef21f6…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Naturepromotional

Mediumprint

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is verbatim and is a genuine 'FDA recommends' sentence, correctly carried into the rule as a recommendation with authority 'guidance' and severity 'note'-level force (warning is defensible given the regulatory backdrop).
- Defect in applies_when / rule scope: in the source this sentence is the second half of the paragraph that begins 'If the proprietary name is not featured but is only part of the running text...'. The recommendation therefore addresses multi-page running text in which the proprietary name is not featured. The rule as written is unconditioned — 'When running text spans more than one page or spread' — so it reads as applying to any multi-page material, including pieces where the proprietary name is featured and the separate II.D.1 allowance (US-NAME-031) governs. That is an obvious limit dropped from the source.
- Determinism 'judgment' is acceptable: although counting appearances is mechanical, deciding what constitutes a single spread versus separate pages is not settled by literal match, and the escalation clause says so.
- Atomic and supported otherwise; the locator (Section II.D.1) is correct and the print-only medium restriction matches that section's heading.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- The quote is a complete, verbatim sentence from Section II.D.1 and is FDA's own recommendation, not a quotation of a regulation - so this is properly drafted from the guidance rather than belonging to 21 CFR 201.10(g)(1)/202.1(b)(1).
- Not overstated: the rule keeps the recommendation as a recommendation ('FDA recommends that the established name accompany ...') rather than converting a 'should' into an obligation, and severity 'warning' is consistent with that.
- The added condition 'Where the proprietary name is not featured but appears only in running text' is justified by the immediately preceding sentence in the source ('If the proprietary name is not featured but is only part of the running text ...'), so the context the quote sits in is preserved rather than invented.
- Atomic: one checkable expectation - established name at least once per page or spread of multi-page running text.
- determinism 'judgment' is defensible: applying it requires deciding whether the proprietary name is 'featured' versus part of running text and where a page or spread boundary falls, which the escalation note also flags.
- authority 'guidance' is correct and not overclaimed; applies_when (promotional, print) matches Section II.D.1's scope of traditional print promotional labeling and advertisements; locator Section II.D.1 is right.
- Violable: a multi-page detail aid whose running text names the brand on every page but the established name only once breaks it.

Nearby rules

US-NAME-031 US-NAME-032 US-NAME-034